Downloading...
Download
ULTRAGENYX PHARMACULTRAGENYX PHARMACULTRAGENYX PHARMAC

ULTRAGENYX PHARMAC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

UP0 chart


Full chart

UP0 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.99 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.206 CHF
Net income (FY)
‪−516.93 M‬ CHF
Revenue (FY)
‪508.80 M‬ CHF
Shares float
‪88.38 M‬
Beta (1Y)
1.06

Employees


Employees (FY)
‪1.29 K‬
Change (1Y)
+18 +1.41%
Revenue / Employee (1Y)
‪393.20 K‬ CHF
Net income / Employee (1Y)
‪−399.48 K‬ CHF

About Ultragenyx Pharmaceutical Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emil D. Kakkis
Website
ultragenyx.com
Headquarters
Novato
Founded
2010
FIGI
BBG00LVGHPH1
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Check out other big names from the same industry as UP0.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

UP0 news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of UP0 is 24.746 CHF — it has decreased by −38.92% in the past 24 hours. Watch ULTRAGENYX PHARMAC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ULTRAGENYX PHARMAC stocks are traded under the ticker UP0.
We've gathered analysts' opinions on ULTRAGENYX PHARMAC future price: according to them, UP0 price has a max estimate of 109.04 CHF and a min estimate of 27.26 CHF. Watch UP0 chart and read a more detailed ULTRAGENYX PHARMAC stock forecast: see what analysts think of ULTRAGENYX PHARMAC and suggest that you do with its stocks.
UP0 reached its all-time high on Sep 1, 2022 with the price of 46.787 CHF, and its all-time low was 24.746 CHF and was reached on Jul 11, 2025. View more price dynamics on UP0 chart.
See other stocks reaching their highest and lowest prices.
UP0 stock is 63.73% volatile and has beta coefficient of 1.06. Track ULTRAGENYX PHARMAC stock price on the chart and check out the list of the most volatile stocks — is ULTRAGENYX PHARMAC there?
Today ULTRAGENYX PHARMAC has the market capitalization of ‪1.99 B‬, it has decreased by −21.79% over the last week.
Yes, you can track ULTRAGENYX PHARMAC financials in yearly and quarterly reports right on TradingView.
ULTRAGENYX PHARMAC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
UP0 earnings for the last quarter are −1.39 CHF per share, whereas the estimation was −1.41 CHF resulting in a 1.74% surprise. The estimated earnings for the next quarter are −1.03 CHF per share. See more details about ULTRAGENYX PHARMAC earnings.
ULTRAGENYX PHARMAC revenue for the last quarter amounts to ‪123.31 M‬ CHF, despite the estimated figure of ‪127.32 M‬ CHF. In the next quarter, revenue is expected to reach ‪128.50 M‬ CHF.
UP0 net income for the last quarter is ‪−133.74 M‬ CHF, while the quarter before that showed ‪−121.14 M‬ CHF of net income which accounts for −10.40% change. Track more ULTRAGENYX PHARMAC financial stats to get the full picture.
No, UP0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 21, 2025, the company has ‪1.29 K‬ employees. See our rating of the largest employees — is ULTRAGENYX PHARMAC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ULTRAGENYX PHARMAC EBITDA is ‪−423.04 M‬ CHF, and current EBITDA margin is −89.33%. See more stats in ULTRAGENYX PHARMAC financial statements.
Like other stocks, UP0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ULTRAGENYX PHARMAC stock right from TradingView charts — choose your broker and connect to your account.